The saga of the discovery of IL-1 and TNF and their specific inhibitors in the pathogenesis and treatment of rheumatoid arthritis

Revue du Rhumatisme (Edition Francaise)

Volumn 69, Issue 3, 2002, Pages 207-217

  Dayer, Jean Michel ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Apolipoprotein A I; IL 1; IL 1Ra; Rheumatoid arthritis; TNF

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; BETA2 INTEGRIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DRUG MECHANISM; HUMAN; LYMPHOCYTE ACTIVATION; MONOCYTE; NONHUMAN; OSTEOLYSIS; OUTCOMES RESEARCH; PROTEIN INTERACTION; REVIEW; RHEUMATOID ARTHRITIS;

EID: 0036208014     PISSN: 11698330     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1169-8330(02)00296-X     Document Type: Short Survey

References (76)

1. Revised nomenclature for antigen nonspecific T cell proliferation and helper factor
2. Collagenase production by rheumatoid synovial cells: Stimulation by a human lymphocyte facrtor
3. 2 release by rheumatoid synovial cells
4. Stimulation of rheumatoid synovial cell collagenase and prostaglandin production by partially purified lymphocyte-activating factor (interleukin 1)
5. 2 production by human synovial cells
6. Bone resorbing activity in supernatant fluid from cultured human peripheral blood leukocytes
7. Macrophage-lymphocyte synergy in the production of osteoclast-activating factor
8. Identification of catabolin, a protein from synovium which induces degradation of cartilage in organ culture
9. Demonstration and characterization of two distinct human leukocytic pyrogens
10. Human leukocytic pyrogen: Purification and development of a radioimmunoassay
11. Potentiation of the T-lymphocyte response to mitogens
12. Human collagenase: Identification and characterization of an enzyme from rheumatoid synovium in culture
13. Production of collagenase and prostaglandins by isolated adherent rheumatoid synovial cells
14. Collenolytic activity in amphibian tissues: A tissue culture assay
15. Prostaglandin production by rheumatoid synovial cells. Stimulation by a factor from human mononuclear cells
16. Biological basis for interleukin-1 in disease
17. An endotoxin induced serum factor that causes necrosis of tumor
18. Purification of cachectin: A lipoprotein lipase suppressing hormone secreted by endotoxin induced raw 264.7 cells
19. 2 production by human synovial cells and dermal fibroblasts
20. Tumor necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage
21. Cytokines and growth factors
22. Pathogenesis of bone erosion in rheumatoid arthritis
23. The role of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption
24. Identification of interleukin-1-like activity and inhibitor(s) in urine from a patient with acute monocytic leukemia
25. 2-stimulating activity (interleukin-1-like) and inhibitor in urine from a patient with monocytic leukaemia
26. 2 and collagenase production by fibroblasts and synovial cells is regulated by urine-derived human interleukin 1 and inhibitor(s)
27. A urine inhibitor of interleukin 1 activity affects both interleukin-1α and 1β but not tumor necrosis factor α
28. Effects of immune complexes on production by human monocytes of interleukin 1 or interleukin 1 inhibitor
29. A urine inhibitor of interleukin 1 activity that blocks ligand binding
30. Specific interleukin-1 inhibitor in serum and urine of children with systemic juvenile chronic arthritis
31. Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist
32. Purification and characterization of a 26-kDa competitive inhibitor of interleukin 1
33. Natural and recombinant human IL-1 receptor antagonists block the effects of IL-1 on bone resorption and prostaglandin production
34. Subcutaneous IL-1 receptor antagonist in patients with rheumatoid arthritis
35. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis
36. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist
37. Anti-interleukin-1 therapy in rheumatic diseases
38. A human inhibitor of tumor necrosis factor α
39. Purification and biologic characterization of a specific tumor necrosis factor α inhibitor
40. Characterization of a tumor necrosis factor α (TNF-α) inhibitor: Evidence of immunological cross-reactivity with the TNF receptor
41. Isolation and characterisation of a tumor necrosis factor binding protein from urine
42. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity
43. Inhibitors of interleukin 1 activity in synovial fluids and in cultured synovial fluid mononuclear cells
44. Soluble tumor necrosis factor receptors in human inflammatory synovial fluids
45. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis
46. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis
47. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
48. The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor
49. Dynamics of fever and the cytokine network in systemic juvenile arthritis
50. Dysregulation of the in vivo production of interleukin-1 receptor antagonist in patients with rheumatoid arthritis
51. Elevated serum levels of interleukin-1 receptor antagonist in polymyositis-dermatomyositis: A biological marker of disease activity with a possible role in the lack of acute-phase protein response
52. Balance between IL-1β, TNF-α, and their specific inhibitors in chronic renal failure and maintenance dialysis
53. Levels of cytokine inhibitors - A possible marker of disease activity in childhood dermatomyositis and polymyositis
54. Low levels of interleukin-1 receptor antagonist coincide with kidney involvement in systemic lupus erythematosus
55. Production of interleukin-1 (IL-1) and a specific IL-1 inhibitor during human monocyte-macrophage differentiation: Influence of GM-CSF
56. Interleukin-1 receptor antagonist: Role in biology
57. Cytokine imbalance in the pathogenesis of rheumatoid arthritis: The role of interleukin-1 receptor antagonist
58. Human Th1 cells preferentially induce interleukin (IL)-1β while Th2 cells induce IL-1 receptor antagonist production upon cell/cell contact with monocytes
59. Uncoupling of inflammatory and destructive mechanisms in arthritis
60. Functions of interleukin 1 receptor antagonist in gene knockout and over-producing mice
61. Altered susceptibility to collagen-induced arthritis in transgenic mice with aberrant expression of interleukin-1 receptor antagonist
62. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice
63. The interaction of immunocompetent cells and chronic inflammation as exemplified by rheumatoid arthritis
64. Cell-cell interactions and collagenase production
65. 3 induce on THP-1 cells distinct patterns of cell surface antigen expression, cytokine production, and responsiveness to contact with activated T cells
66. Expression and cleavage of tumor necrosis factor α and tumor necrosis factor receptors by human monocytic cell lines upon direct contact with stimulated T cells
67. Direct contact between T lymphocytes and monocytes is a major pathway for induction of metalloproteinase expression
68. CCR5 is characteristic of Th1 lymphocytes
69. Cell surface glycoproteins expressed on activated human T cells induce production of interleukin-1 beta by monocytic cells: A possible role of CD69
70. CD40-CD40 ligand (CD154) engagement is required but may not be sufficient for human T helper 1 cell induction of IL-2- or IL-15-driven, contact-dependent, IL-1β production by monocytes
71. Imbalance between interstitial collagenase (MMP-1) and tissue inhibitor of metalloproteinases-1 (TIMP-1) in synoviocytes and fibroblasts upon direct contact with stimulated T lymphocytes: Involvement of membrane-associated cytokines
72. Modulation of soluble and membrane-bound TNF-induced phenotypic and functional changes of human brain microvascular endothelial cells by recombinant TNF binding protein I
73. Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor α production in rheumatoid arthritis
74. Interleukin-18, rheumatoid arthritis, and tissue destruction
75. Contribution of interleukin-17 to synovium matrix destruction in rheumatoid arthritis
76. Apolipoprotein A-1 inhibits the production of interleukin-1β and tumor necrosis factor-α by blocking contact-mediated activation of monocytes by T lymphocytes